{"id":"NCT02487225","sponsor":"Mayo Clinic","briefTitle":"Pentoxifylline Treatment in Acute Pancreatitis (AP)","officialTitle":"Pentoxifylline Treatment in Acute Pancreatitis: A Double-Blind Placebo - Controlled Randomized Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-05","primaryCompletion":"2017-04-30","completion":"2017-10-31","firstPosted":"2015-07-01","resultsPosted":"2019-01-23","lastUpdate":"2019-01-23"},"enrollment":83,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Pancreatitis (AP)","Gallstone Pancreatitis","Alcoholic Pancreatitis","Trauma Acute Pancreatitis","Hypertriglyceridemia Acute Pancreatitis","Idiopathic (Unknown) Acute Pancreatitis","Medication Induced Acute Pancreatitis","Cancer Acute Pancreatitis","Miscellaneous (i.e. Acute on Chronic Pancreatitis)"],"interventions":[{"type":"DRUG","name":"Pentoxifylline","otherNames":["Trental","Pentox","Pentoxil","Flexital"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pentoxifylline","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to determine the effects (good and bad) of giving a drug called pentoxifylline to patients with acute pancreatitis.","primaryOutcome":{"measure":"Change in C-reactive Protein (C-RP) From Admission Baseline at One Week.","timeFrame":"Admission (baseline), day 5","effectByArm":[{"arm":"Pentoxifylline","deltaMin":86.2,"sd":81.5},{"arm":"Placebo","deltaMin":75.8,"sd":83.1}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5796"},{"comp":"OG000 vs OG001","p":"0.8415"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":45},"commonTop":["Headache/Migraine","Nausea","Sepsis due to disease progression","Angina","Necrosis due to disease progression"]}}